SJN DO CB Field Alert Reports. Edwin Ramos Director of Compliance Food and Drug Administration San Juan District Office
|
|
- Lorin Carson
- 6 years ago
- Views:
Transcription
1 SJN DO CB Field Alert Reports Edwin Ramos Director of Compliance Food and Drug Administration San Juan District Office
2 SJN DO Mission Assuring that safe and effective drugs are available to the public Reduce public health risks associated with the quality, safety, and effectiveness of the nation's marketed drugs High-quality pharmacovigilance and risk minimization practices Utilize strategic problem solving to identify, evaluate, and prioritize risks related to drug quality, safety, effectiveness, and availability
3 SJN DO CB Review the Violations Analyze the Violations Consider Desired Outcome Optimize Compliance Decisions Pursue Compliance Decision with Energy Follow 7 Cardinal Rules
4 Review the Violations SJN DO CB Evidence collected Regulatory significance of each observation DP risk analysis or immediate HH Analyze the Violations Examine evidence Impact to FDP Identification of relevant agency policy Determine adulteration charge provisions of law and regulations Develop a charging scheme
5 SJN DO CB Consider the Desired Outcome Compliance with Pre-approval Regulation Manufacturing Regulation Post-approval Regulation Removal of adulterated, misbranded or unapproved drug products from market or withhold approval Optimize Compliance Decision HH of product on the market, if necessary History of significant, uncorrected violations Significant violations but no immediate HH or violative history
6 SJN DO CB Pursue Decisions with Energy Compliance Actions are taken for violations of law Law is in place to Promote and Protect Public Health Desired outcome is, must be a top priority Follow 7 Cardinal Rules of a Compliace Officer
7 SJN-DO Legal Actions FY 2009 Warning Letters Issued: 11 Food: 6 Medical Gas: 1 Devices: 2 OTC: 1 Blood Bank: 1 Untitled Letters Issued: 2 Food - 2 Regulatory Meetings: 5 Food: 2 OTC: 1 Post-WL Devices: 2 Post-WL
8 WL Close-Out Letter Program WL issued after September 1, 2009 When based on FDA s s evaluation the firm has taken corrective actions Corrective actions must have been implemented by firm and verified by FDA DO will issue the close-out out letter? - WLcloseoutprocess@fda.hhs.gov
9 21 CFR effective 5/23/85 PART APPLICATIONS FOR FDA APPROVAL TO MARKET A NEW DRUG Sec Other postmarketing reports. (a) Applicability. Each applicant shall make the reports for each of its approved applications and abbreviated applications required under this section and section 505(j) and section 507(g) of the act.
10 The report and its mailing cover should be plainly marked: NDA--Field Alert Report'' (i) Information concerning any incident that causes the drug product or its labeling to be mistaken for, or applied to, another article. (ii) Information concerning any bacteriological contamination, or any significant chemical, physical, or other change or deterioration in the distributed drug product, or any failure of one or more distributed batches of the drug product to meet the specifications established for it in the application.
11 (b) Reporting requirements. The applicant shall submit to the FDA at the specified times two copies of the following reports: (1) NDA--Field Alert Report. The applicant shall submit specific information about distributed drug products to the jurisdictional FDA DO that is responsible for the facility involved within 3 working days of receipt by the applicant.
12 21 CFR (1)(i) Required Reporting Any incident that causes the drug product or its labeling to be mistaken for, or applied to, another article Confirmed and unconfirmed products
13 21 CFR (1)(ii) Required Reporting Bacterial contamination Significant chemical, physical or other changes Product deterioration Product out-of of-specification
14 Primary Defects Reported Delivery System 10% Examples Fill problem 4% ADR 18% Contaminated/ sterility 3% Formulation/ substitution 22% Other 9% Packaging 6% Labeling Product defect 14% 14
15 Reporting Requirements Applicant holders are required to submit NDA/ANDA FAR on drug products manufactured or distributed within or outside the U.S. U.S. Office/Agent - responsible for reporting to jurisdictional FDA DO (registered or located) Notify the DO within 33 working days
16 Reporting Requirements Information may be provided by telephone or other rapid communication means, with prompt written follow-up Form FDA 3331 standardized form Internet Availability cder.html
17 Changes to FDA 3331 Line 13- include Root Cause(s) ) of the Problem(s) ) in an effort to obtain more info from the applicant and better assess the problem Compliance Program , Drug Quality Reporting System, NDA FAR is being revised
18 33 Working Days Required to Report Regulatory Clock Begins: Firm becomes aware of a reportable problem Complaint Internal testing Unconfirmed problem Confirmed problem
19 FAR Required Firm Reporting Further investigation required Determine the root cause Corrective action initiated e.g., formulation revision, labeling change Product Recall FAR is not Required Problem is resolved within 3 working days, such as, analytical lab error
20 Investigation Date/OOS #/Brief Subject Heading Author/investigator Product name/affected lot number (s) Clear statement of the reason for investigation Root cause analysis of investigation Evaluation of impact on previous and subsequent lots Personnel interviews Audit of procedures, records, and lab-books books Conclusion - root cause of OOS (if found) Corrective/preventive actions, if needed
21 Investigation For those extending beyond the lab must follow an outline with particular attention to corrective action. The firm should: State the reason for the investigation Provide recap of the process sequences that may have caused the problem Outline CA necessary to save the batch and prevent similar recurrence rence List other batches/products possibly affected, the results of investigation of these batches and products, and any corrective action Specifically: examine other batches of product made by the errant employee or machine examine other products produced by the bad process or operation preserve the comments and signatures of all production and QC personnel who conducted the investigation and approved any reprocessed material after additional testing
22 District Responsibilities Submit a copy of each FAR Initial within 5 working days Follow-up in a timely manner Final Upon receipt and district evaluation
23 District Responsibilities Submit DO action plan Available investigational information Assess significance of FAR Conduct appropriate follow-up Determine compliance with regulation Routine inspections Pre-approval inspections
24 District Responsibilities Receive all FARS Designates a Drug Field Alert Monitor Assess significance of FAR FAR complies with regulation Evaluates firm s s root cause analysis & CAPA Monitors the progress and completion of the firm s s CAPA Forward FARs to CDER/DCRMS within 5 working days after receipt
25 District Responsibilities Request from applicant holder: Laboratory reports Investigational reports Sample collection Other documents with info used to Id or determine root cause of the problem Time lines for initiating and completing investigations, if needed.
26 Division of Compliance Risk Management & Surveillance Program Team Rapidly identify all potential health hazards associated with product use Detect industry problems and trends Unacceptable risks identified Operate a centralized reporting system
27 DCRMS Program Team Liaison between DO and CDER Manages all NDA FARs Coordinates inspectional & regulatory activities Receives all domestic and foreign related FARs and enters into DQRS database for further evaluation
28 DCRMS Program Team Evaluates all FARs,, EIR, & corrective actions Consults with appropriate CDER Review Divisions Provides consults/guidance to DO Monitors progress & completion of related investigations & corrective actions Recommends/approves appropriate regulatory action re: firm s s failure to comply with 21 CFR (b)(i)(ii)
29 DCRMS Workflow Receive Report Code Defect Code Severity Determine further actions Enter Report In Database Send Report to District Company Other Offices Issue Assignment if needed Follow-up
30 DCRMS Program Team Screen all reports Responsibilities Review/Evaluate Potential Health Hazard Prioritize Priority 1 - Imminent or serious health hazard Priority 2 - Potentially significant cgmp problems Priority 3 - Routine follow-up
31 CDER OC HFD-330 Approves regulatory actions re: FAR reporting Warning Letter, if appropriate Significance of violation(s) Previously cited violation(s) Concurrence with HQ
32 WL Citation Example Failure to submit NDA Field Alert Reports (FAR) within 3 working days of becoming aware of information concerning any significant chemical, physical, or other change or deterioration in the distributed drug product as required under 21 CFR For example, regarding the unknown peaks that were detected for Product A and Product B, your findings from the inspection show that the unknown peak was initially identified in June 2008 and your investigation of this peak was approved and closed by your firm in August However, the FAR was issued on November, 2008, during the FDA's inspection of your facility. Neither the records reviewed by the investigators, nor the information submitted with your response to the FDA-483 includes a justification or rationale for your decision to not submit a FAR to the FDA's SJD DO in a timely manner
33 WL Citation Example 1. For example, the agency was not notified, in accordance with NDA Field Alert reporting requirements, when it was determined that lot 1234, ERR Tablets USP 0.10 mg, failed impurity and dissolution testing at the 9 month of prescribed stability testing interval as reported for your on-going LT room temperature stability study.
34 CDER Review Divisions Responsibilities Review FAR Determine completeness for review Assure any corrective action(s) ) is not in conflict with NDA/ANDA requirements Assures that a supplement has been submitted and approved for the NDA/ANDA FAR becomes part of the approved NDA/ANDA 34
35 Promoting and Protecting Public Health The intent of the 21 CFR regulation is to establish an early warning system so that significant problems are brought to the Agency's attention by applicant holders in order to prevent potential safety hazards from drug products already in distribution.
36 Impact on Public Health Protection Recalls (types see 21 CFR Section 7.3) Corrective Actions Discontinuation of products
Complaints Investigation and Review. Dr. Ademola Daramola International Relations Specialist Drugs US FDA India Office New Delhi February 22nd 2018
Complaints Investigation and Review Dr. Ademola Daramola International Relations Specialist Drugs US FDA India Office New Delhi February 22nd 2018 Information presented in this presentation does not represent
More informationCenter for Drug Evaluation and Research - Compliance Central with FDA Center Compliance Directors: Part 1
Center for Drug Evaluation and Research - Compliance Central with FDA Center Compliance Directors: Part 1 Donald D. Ashley, JD 2017 FDLI Enforcement, Litigation, and Compliance Conference: For the Drug,
More informationBristol Myers Squibb Holdings Pharma., Ltd.
Bristol Myers Squibb Holdings Pharma., Ltd. Department of Health and Human Services Public Health Service Food and Drug Administration 466 Fernandez Juncos Avenue Puerta De Tierra San Juan, Puerto Rico
More informationAMENDED WARNING LETTER CIN
Department of Health and Human Services Public Health Service Food and Drug Administration Cincinnati District Office Central Region 6751 Steger Drive Cincinnati, OH 45237-3097 Telephone: (513) 679-2700
More information2015 Annual FDA Medical Device Quality System Data. Inspections, FDA Form 483 Observations, and Warning Letter Citations
2015 Annual FDA Medical Device Quality System Data Inspections, FDA Form 483 Observations, and Warning Letter Citations Why is FDA making these data available? In support of the FDA s Transparency and
More informationThe FDA Food Safety Modernization Act of 2009 Section-by-Section Summary
The FDA Food Safety Modernization Act of 2009 Section-by-Section Summary Title I Improving Capacity to Prevent Food Safety Problems Sec. 101. Inspection of Records Gives FDA expanded access to food facility
More informationPostmarketing Drug Safety and Inspection Readiness
Postmarketing Drug Safety and Inspection Readiness June 19, 2018 Center for Drug Evaluation and Research (CDER) Small Business and Industry Assistance (SBIA) Webinar United States Food and Drug Administration
More informationFDA s Office of Regulatory Affairs: Violation Trends & Medical Device Update
FDA s Office of Regulatory Affairs: Violation Trends & Medical Device Update Ginger M. Sykes Supervisory Consumer Safety Officer Salt Lake City Resident Post Office of Regulatory Affairs U.S. Food and
More informationChapter 48 - Bioresearch Monitoring
COMPLIANCE GUIDANCE MANUAL Chapter 48 - Bioresearch Monitoring Subject SPONSORS, CONTRACT RESEARCH ORGANIZATIONS AND MONITORS Implementation Date February 21, 2001 Completion Date Continuing Product Codes
More informationFDA's OMB supporting document for QSr recordkeeping, 7/20/01, page 1 of 7
FDA's OMB supporting document for QSr recordkeeping, 7/20/01, page 1 of 7 DISCLAIMER: This document was prepared by editing the converted PDF file supporting FDA's request to OMB for continuation of record
More informationBE-595M Homework Assignment Due: 3/3/08
BE-595M Homework Assignment Due: 3/3/08 Attached is a Warning Letter issued to Applied Water Engineering, Inc., Salt Lake City, UT, for violations of the Quality System Regulations. The firm manufactures
More informationChanging Requirements for Devices//Device Constituent Parts in Combination Products
Changing Requirements for Devices//Device Constituent Parts in Combination Products Dan Wozinski, RPH, MBA Sanofi Disclaimer The content and viewpoints of this presentation are mine alone and not those
More informationGuidance for Industry ANDA Submissions Prior Approval Supplements Under GDUFA
Guidance for Industry ANDA Submissions Prior Approval Supplements Under GDUFA DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this
More informationFSMA User Guide. Food Safety Modernization Act Guide
Food Safety Modernization Act Guide The Food Safety Modernization Act of 2011 (FSMA), the first major overhaul of food safety legislation in more than 70 years, gives FDA the new job of building a modern,
More informationPREVENT YOUR DIETARY SUPPLEMENT LABORATORY FROM BECOMING A COMPLIANCE RISK. Marian Boardley 2013
PREVENT YOUR DIETARY SUPPLEMENT LABORATORY FROM BECOMING A COMPLIANCE RISK Marian Boardley 2013 APPLICABLE GMP S: DIETARY SUPPLEMENT LABS Subparts for laboratory operations and testing, 21 CFR 111 D Equipment
More informationDetermining and Reporting Adverse Events vs. Product Complaints
Determining and Reporting Adverse Events vs. Product Complaints Pharma Perspective: Jacqueline Grissinger Director, Office of Consumer Medical Safety Johnson & Johnson Medical Device Perspective: Lisa
More informationCBI s 14 th ANNUAL PRODUCT COMPLAINTS CONGRESS FOR LIFE SCIENCES June 14, 2016
CBI s 14 th ANNUAL PRODUCT COMPLAINTS CONGRESS FOR LIFE SCIENCES June 14, 2016 UPDATE ON FDA GUIDANCE AND REGULATIONS FOR THE COMPLAINT HANDLING PROCESS AND ON FDA FIELD ALERT REPORTS By Peter S. Reichertz
More informationGuidance for Industry
Guidance for Industry Self-Identification of Generic Drug Facilities, Sites, and Organizations DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions
More informationComplaint Handling and Medical Device Reporting (MDRs)
Complaint Handling and Medical Device Reporting (MDRs) FDA Small Business Regulatory Education for Industry (REdI) Bethesda, MD September 26, 2013 Andrew Xiao Consumer Safety Officer, Postmarket and Consumer
More informationSolutions for GCP Compliance Challenges. September 23, 2015 Northwestern University IRB Brown Bag Session
Solutions for GCP Compliance Challenges September 23, 2015 Northwestern University IRB Brown Bag Session PAMELA MASON, MPH Vice President, Mason Professional Services, LLC Adjunct Faculty, Northwestern
More informationSolutions for GCP Compliance Challenges
Solutions for GCP Compliance Challenges September 23, 2015 Northwestern University IRB Brown Bag Session PAMELA MASON, MPH Vice President, Mason Professional Services, LLC Adjunct Faculty, Northwestern
More informationWIRBinar. How to Survive an FDA Inspection. Upcoming Trainings: Contact Us: (360)
WIRBinar How to Survive an FDA Inspection 10-26-2011 Brought to you by WIRB Education and Consulting Services. Improve your ability to maintain compliance and protect human subjects with guidance from
More informationRe: Docket No. FDA 2013-N-0500 Proposed Rule: Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products
March 13, 2014 BY ELECTRONIC DELIVERY Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA 2013-N-0500 Proposed Rule: Supplemental
More informationCompounded Sterile Preparations Pharmacy Content Outline May 2018
Compounded Sterile Preparations Pharmacy Content Outline May 2018 The following domains, tasks, and knowledge statements were identified and validated through a role delineation study. The proportion of
More informationFDA Reauthorization Act of 2017 (FDARA)
FDA Reauthorization Act of 2017 (FDARA) April 4, 2018 PRESENTED BY: Jessica Ringel Counsel FDA & Life Sciences Practice Group King & Spalding LLP (202) 626-9259 jringel@kslaw.com FDA Reauthorization Act
More informationIntroduction to Post-marketing Drug Safety Surveillance: Pharmacovigilance in FDA/CDER
Introduction to Post-marketing Drug Safety Surveillance: Pharmacovigilance in FDA/CDER Sara Camilli, PharmD, BCPS, Safety Evaluator Team Leader Selena Ready, PharmD, CGP, Safety Evaluator Division of Pharmacovigilance
More informationRemediation, Resolution and Outcomes
IPA Pharmaceutical Forum 2018 22-23 February 2018 Presented by Andrei Spinei Manufacturing and Quality Compliance, European Medicines Agency An agency of the European Union Contents 1.EMA EU Network 2.Remediation
More informationDraft 11/3/2017. Crosswalk - Requirements for Foodborne Illness Training Programs Based on Standard 5
Draft 11/3/2017 Crosswalk - Requirements for Training Programs Based on Standard 5 Introduction: The 2012 2014 Interdisciplinary Training Committee (IFITC) obtained the Food Safety and Modernization Act
More informationCrosswalk - Requirements for Foodborne Illness Training Programs Based on Standard 5
Crosswalk - Requirements for Training Programs Based on Standard 5 Introduction: The 2012 2014 Interdisciplinary Training Committee (IFITC) obtained the FSMA 205 C(1) Phases of a Food Incident (CIFOR/RRT/MFRPS/VNRFRPS
More informationMay 12, 2016 MEMORANDUM. Certain provisions of FSMA are already in effect, namely: Mandatory recall authority (FSMA 206).
L A W O F F I C E S 7 0 0 T H I R T E E N T H S T R E E T, N. W. S U I T E 1 2 0 0 W A S H I N G T O N, D. C. 2 0 0 0 5-5 9 2 9 ( 2 0 2 ) 7 3 7-5 6 0 0 F A C S I M I L E ( 2 0 2 ) 7 3 7-9 3 2 9 w w w.
More informationHow to Conduct Robust Root Cause Investigations for CAPA (Corrective and Preventive Action)
How to Conduct Robust Root Cause Investigations for CAPA (Corrective and Preventive Action) Celebrating 50 YEARS 1 9 6 7-2 0 1 7 March 27-28, 2017 Burlingame, CA Course Topics Include: Describing the Problem
More informationCAP Most Frequent Deficiencies and How to Avoid Them. March 11, 2015
CAP 2015 Most Frequent Deficiencies and How to Avoid Them Jean Ball MBA,MT(HHS),MLT(ASCP) Inspection Services Team Lead Laboratory Accreditation Program March 11, 2015 Objectives: Participants will be
More informationINTRODUCTION TO HACCP
INTRODUCTION TO HACCP NINA G. PARKINSON NGP CONSULTING NOVEMBER 12, 2014 NGP Consulting Nov 2014 1 COMMENTS FROM 2013 Waaay too much information! Didn t even get to the end with FSMA stuff! Basic, but
More informationInspections, Compliance, Enforcement, and Criminal Investigations
1 of 5 2/11/2014 11:24 AM Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Baxter
More informationVersion 1.1, 6/30/2016 Guidance for Abbreviated IDE Requirements
Version 1.1, 6/30/2016 Guidance for Abbreviated IDE Requirements The Principal Investigator of a study that is requesting an abbreviated IDE for use of a non-significant risk device must attest to the
More informationPOLICY OFFICE OF PHARMACEUTICAL QUALITY
POLICY OFFICE OF PHARMACEUTICAL QUALITY Requests for Expedited Review of New Drug Application and Biologics License Application Prior Approval Supplements Submitted for Chemistry, Manufacturing, and Controls
More informationGuidance for Industry
Guidance for Industry Electronic Submission of Lot Distribution Reports for Biological Products This guidance is for immediate implementation. FDA is issuing this guidance for immediate implementation
More informationThe U.S. Food and Drug Administration s Food Safety Modernization Act: Current & Future Requirements
The U.S. Food and Drug Administration s Food Safety Modernization Act: Current & Future Requirements Beatrice Moreau Senior Regulatory Advisor Registrar Corp 144 Research Drive Hampton, Virginia USA 23666
More informationPATIENT INFORMATION. In Case of Emergency Notification
PATIENT INFORMATION Patient Name Date Nickname DOB Age Sex Race/Ethnicity Language(s) spoken at home Person completing form Relation to Patient Patient Address City State Zip Phone # Other Phone Medical
More informationMedical Devices: Do I Need to Open a CAPA?
Medical Devices: Do I Need to Open a CAPA? Adrienne Franco Busby, Partner, Faegre Baker Daniels LLP Anne Miller, Principal Regulatory Counsel, Medtronic Marta L. Villarraga, Principal, Exponent, Inc. Moderated
More informationStandards, Guidelines, and Regulations
Standards, Guidelines, and Regulations Theresa C. Stec BA, MT(ASCP) Biovigilance Program Manager Surgical System Administrator Perioperative Services Baystate Medical Center Springfield, MA Standards,
More informationAre You Ready for FSMA? Janet Raddatz VP Quality & Food Safety Systems Sargento Foods Inc. WAFP June 12, 2013
Are You Ready for FSMA? Janet Raddatz VP Quality & Food Safety Systems Sargento Foods Inc. WAFP June 12, 2013 New Responsibilities for Food Companies Impacting daily operations in all registered facilities,
More informationSECTION HOSPITALS: OTHER HEALTH FACILITIES
SECTION.1400 - HOSPITALS: OTHER HEALTH FACILITIES 21 NCAC 46.1401 REGISTRATION AND PERMITS (a) Registration Required. All places providing services which embrace the practice of pharmacy shall register
More informationWARNING LETTER CERTIFIED MAIL -~ Q December 14, 2005
-~ Q DEPARTMENT Or HEALTI-I A\D HUMAN SERVICES Public Health Service Food and Drug Administration Central Region Telephone (973) 526-6006 New Jersey District Waterview Corporate Center 10 Waterview Blvd.,
More informationChemical Biological Defense Materiel Reliability Program
Army Regulation 702 16 Product Assurance Chemical Biological Defense Materiel Reliability Program Headquarters Department of the Army Washington, DC 2 May 2016 UNCLASSIFIED SUMMARY of CHANGE AR 702 16
More informationDocumenting the Story of a Clinical Trial: Concept to CAPA. Lori T. Gilmartin Gilmartin Consulting LLC
Documenting the Story of a Clinical Trial: Concept to CAPA Lori T. Gilmartin Gilmartin Consulting LLC The regulations represent the floor while ethical thinking is the sky. Dr. Thomas Moore Boston University
More informationStay Compliant! Electronic Submission of Drug Master Files (DMFs) is MANDATORY starting May 5, 2017: What You Need to Know
CDER SBIA Webinar Series Stay Compliant! Electronic Submission of Drug Master Files (DMFs) is MANDATORY starting May 5, 2017: What You Need to Know Jonathan Resnick, Project Management Officer Division
More informationOrientation to Risk Evaluation and Mitigation Strategies (REMS)
Orientation to Risk Evaluation and Mitigation Strategies (REMS) Gary Slatko, MD Director, Off of Medication Error Prevention and Risk Management, OSE, CDER, FDA September 25, 2013 1 Background The REMS
More informationInjury and Work-Related Illness Prevention Program
Associated Students, California State University, Northridge, Inc. Injury and Work-Related Illness Prevention Program 1. PURPOSE STATEMENT It is the intention of the Associated Students, California State
More informationConnie Hoy October 2013
Connie Hoy October 2013 Warning letter issued to firm for complaint handling Failure to report within 30 days Failure to implement adequate procedures Failure to establish standard review process No procedure
More informationFDA Inspectional Process in Clinical Research An FDA Perspective. Annette Melendez, MPHsN Investigator Office of Biological Products Operations
FDA Inspectional Process in Clinical Research An FDA Perspective Annette Melendez, MPHsN Investigator Office of Biological Products Operations Outline BIMO PROGRAM OVERVIEW PROGRAM COVERED AREAS INSPECTIONAL
More informationFood Safety Modernization Act (FSMA)
Food Safety Modernization Act (FSMA) FDA FSMA Timeline July 29, 2009 House version passed Votes 283-142 Nov. 30, 2010 Senate version passed Votes 73-25 Dec. 19, 2010 Senate revised version passed Unanimous
More informationRegulatory,Quality & Emergency Preparedness. MaryBeth Parache Director, Quality Affairs New York Blood Center
Regulatory,Quality & Emergency Preparedness MaryBeth Parache Director, Quality Affairs New York Blood Center 1 Regulatory 2 Who regulates us? Food and Drug Administration (FDA) Blood, tissue, HCT/P, medical
More information1. Review the scenario, resource list, and scenario map in your handouts.
Unit 2. ICS Fundamentals INSTRUCTOR NOTES UNIT 2: PET FOOD RECALL SCENARIO Objective: To review the key concepts of ICS. Instructions: Ask the participants to work in teams to complete the following activity:
More informationStandards for the Operation of Licensed Pharmacies
Standards for the Operation of Licensed Pharmacies Introduction These standards are made under the authority of Section 29.1 of the Pharmacy and Drug Act. They are one component of the law that governs
More informationLCDR Kemi Asante, PharmD, RAC Health Science Policy Analyst Office of Prescription Drug Promotion CDER FDA
Providing Regulatory Submissions in Electronic and Non-Electronic Format Promotional Labeling and Advertising Materials for Human Prescription Drugs Draft Guidance for Industry LCDR Kemi Asante, PharmD,
More informationRRT Manual A Resource for Standard 5 Panel Discussion on RRT Cooperative Agreement Program States
RRT Manual A Resource for Standard 5 Panel Discussion on RRT Cooperative Agreement Program States Rapid Response Team Best Practices Manual - MFRPS Training Kansas City 2012 Sample Timeline for Manufactured
More informationPOCKET GUIDE TO THE ACCREDITATION STANDARDS (ISO 15189:2014)
(GLENMARIE BRANCH) POCKET GUIDE TO THE ACCREDITATION STANDARDS (ISO 15189:2014) Know the requirement!! Prepared by: Dr.Lily Manorammah Contents INTRODUCTION:... 3 OUR STRATEGY... 3 MANAGEMENT REQUIREMENTS...
More informationCHAPTER 246. C.App.A:9-64 Short title. 1. This act shall be known and may be cited as the "New Jersey Domestic Security Preparedness Act.
CHAPTER 246 AN ACT concerning domestic security preparedness, establishing a domestic security preparedness planning group and task force and making an appropriation therefor. BE IT ENACTED by the Senate
More informationFood Safety Modernization Act
Aon Risk Solutions Food Safety Modernization Act Highlights and Implications for Your Business Risk. Reinsurance. Human Resources. On January 4, 2011, President Obama signed the Food Safety Modernization
More informationPLAN OF ACTION FOR IMPLEMENTATION OF 510(K) AND SCIENCE RECOMMENDATIONS
PLAN OF ACTION FOR IMPLEMENTATION OF 510(K) AND SCIENCE RECOMMENDATIONS In August 2010, the Food and Drug Administration s Center for Devices and Radiological Health (CDRH or the Center) released for public
More informationFDA HAS MADE PROGRESS
Department of Health and Human Services OFFICE OF INSPECTOR GENERAL FDA HAS MADE PROGRESS ON OVERSIGHT AND INSPECTIONS OF MANUFACTURERS OF GENERIC DRUGS Daniel R. Levinson Inspector General May 2015 OEI-01-13-00600
More informationFDA. Office of Criminal Investigations
FDA Office of Criminal Investigations Established in March 1992 by the Commissioner, with the urging of Congress, in response to concerns of increased criminal violations of the Act 1 OCI Mission Statement
More informationIQCP. Ensuring Your Laboratory s Compliance With Individualized Quality Control Plans. November/December 2016
IQCP Ensuring Your Laboratory s Compliance With Individualized Quality Control Plans November/December 2016 Objectives Describe the different components of an IQCP Review new CAP checklist requirements
More informationDepartment of Environmental Health and Safety Laboratory Inspection Protocol
1.0 Introduction Laboratory inspections are required by the Occupational Safety and Health Act (OSHA) Laboratory Standard and serve as key elements of the (NYMC) policy to ensure a safe, healthy working
More informationTomoko OSAWA, Ph.D. Director for GCP Inspection Office of Conformity Audit PMDA, Japan
Tomoko OSAWA, Ph.D. Director for GCP Inspection Office of Conformity Audit PMDA, Japan The views presented in this presentation are those of the author and should not be understood or quoted as being made
More information[date] Health Net s Medicare Advantage and Dual Eligible Programs Issue Write-Up Form - Instructions for Completion
Health Net s Medicare Advantage and Dual Eligible Programs Issue Write-Up Form - Instructions for Completion This process is not related to and is separate from any provider appeals processes. Consider
More informationPost Market Surveillance Requirements. SAMED Regulatory Conference 2 December 2015
Post Market Surveillance Requirements SAMED Regulatory Conference 2 December 2015 Topics Surveillance & Vigilance Adverse Events Reportable Adverse Events Reporting Adverse Events Time frames Exemptions
More information3/14/2016. The Joint Commission and IQCP. Objectives. Before Getting Started
The Joint Commission and IQCP Stacy Olea, MBA, MT(ASCP), FACHE Executive Director Laboratory Accreditation The Joint Commission AACC 2015 Objectives Identify the three components of IQCP Determine a starting
More informationFSMA Implementation FDA s Preventive Controls Rules
FSMA Implementation FDA s Preventive Controls Rules 2016 National Association of Dairy Regulatory Officials Annual Meeting July 11, 2016 CAPT Robert (Bob) Hennes, MST Leader Presentation Overview FSMA
More informationAdministrative Policies and Procedures. Policy No.: N/A Title: Medical Equipment Management Plan
Administrative Policies and Procedures Originating Venue: Environment of Care Title: Medical Equipment Management Plan Cross Reference: Date Issued: 11/14 Date Reviewed: Date: Revised: Attachment: Page
More informationAuthorized Personnel to Review
October 31, 2017 Page 1 of 7 All documents developed or maintained for the Manufactured Food Regulatory Program Standards ( MFRPS ) are listed below. For each document, the following information is included:
More informationLaboratory Risk Assessment: IQCP and Beyond. Ron S. Quicho, MS Associate Project Director Standards and Survey Methods, Laboratory July 18, 2017
Laboratory Risk Assessment: IQCP and Beyond Ron S. Quicho, MS Associate Project Director Standards and Survey Methods, Laboratory July 18, 2017 Objectives Explain the importance of risk assessment in the
More informationSafety Best Practices Manual
CHAPTER 23 OSHA Compliance Inspection Policy POLICY It is the policy of the Flight Department to comply with all applicable government regulations concerning the safety and health of employees. It is also
More informationReceived an RTA Deficiency List or AI Letter? Now What?
Received an RTA Deficiency List or AI Letter? Now What? Dealing with Unexpected Issues/Questions during the Submission Review Process Navigating Submission Challenges to reduce time & risk September 26,
More informationBetter Medical Device Data Yield Improved Care The benefits of a national evaluation system
A fact sheet from Aug 2016 Better Medical Device Data Yield Improved Care The benefits of a national evaluation system Overview The current system for evaluating implanted medical devices provides inadequate
More informationNew England District Update FDA s Office of Regulatory Affairs Aligns for the Future
New England District Update FDA s Office of Regulatory Affairs Aligns for the Future MassMedic December 12, 2017 Waltham, MA Joseph S. Matrisciano Jr, JD, PE Director, New England District Director, Office
More informationModernizing Hospital Adverse Event Reporting
Modernizing Hospital Adverse Event Reporting 14 December 2016 Sarah H. Stec Not Legal Advice For Informational and Educational Purposes Only Firm Overview More than 1,500 lawyers in 46 offices across 21
More informationFSMA Update. Samantha Shinbaum. October 3, 2017
FSMA Update Samantha Shinbaum October 3, 2017 Background Information A Little About Me Received my Bachelors from the University of Florida. Received my Masters from the University of Arkansas. Working
More informationPolicy Subject Index Number Section Subsection Category Contact Last Revised References Applicable To Detail MISSION STATEMENT: OVERVIEW:
Subject Objectives and Organization Pathology and Laboratory Medicine Index Number Lab-0175 Section Laboratory Subsection General Category Departmental Contact Ekern, Nancy L Last Revised 10/25/2016 References
More informationSterile Compounding: Highlights of the New Law
Patricia C. Kienle, RPh, MPA, FASHP Director, Accreditation and Medication Safety Cardinal Health Innovative Delivery Solutions Sterile Compounding: Highlights of the New Law 2 Please explain the difference
More informationFSMA Enforcement: The First Year
FSMA Enforcement: The First Year Scott J. MacIntire Director, Division of Enforcement FDA Office of Regulatory Affairs December 6, 2017 Topics to Include Compliance & Enforcement FSMA Inspections Human
More informationEHR] A INSPECTION REPORT. Guy s Hospital Pharmacy St Thomas Street London SE1 9RT. Safeguarding public health
Safeguarding public health EHR] A INSPECTION REPORT Guy s Hospital Pharmacy St Thomas Street London SE1 9RT Head Office: Inspection & Standards Division, Market Towers, I Nine Elms Lane, Vauxhall, London,
More informationSession 3 FDA Audits and Findings
Session 3 FDA Audits and Findings Byungja Marciante, Investigator US Food and Drug Administration Shanghai Centre-Suite 723 1376 Nanjing Xi Lu Shanghai, PRC 200040 美国食品药品管理局上海商城 723 室南京西路 1376 号中国上海 200040
More informationBIMO Program Update an operational perspective
BIMO Program Update an operational perspective Clinical Trials Summit San Juan, Puerto Rico May 9, 2018 Anne E. Johnson Program Division Director FDA/ORA/OBIMO Division I (East) 1 Objectives Program Alignment
More informationSubmitted electronically via: May 20, 2015
Submitted electronically via: http://www.regulations.gov May 20, 2015 Jane Axelrad, JD Associate Director for Policy, CDER Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers
More informationPHARMACY SERVICES/MEDICATION USE
25.01. 10 Drug Reactions & Administration Errors & Incompatibilities. Drug administration errors, adverse drug reactions and incompatibilities must be immediately reported to the attending physician and
More informationINJURY AND ILLNESS PREVENTION PLAN (IIPP) October 2015
INJURY AND ILLNESS PREVENTION PLAN (IIPP) October 2015 Policies and Procedures Office of Environmental Health & Safety TABLE OF CONTENTS IIPP Information iii Building Contact iv Designated Emergency Medical
More informationUpdate on FSMA Implementation. Rebecca Buckner May 24, 2016
Update on FSMA Implementation Rebecca Buckner May 24, 2016 Presentation Overview FSMA Implementation Rulemaking and Industry Guidance - Focus on the Preventive Controls Rules FSMA Implementation Guiding
More informationMedical Device Recall Report FY FY 2012
Medical Device Recall Report FY 2003- FY 2012 Ann Ferriter Division of Analysis and Program Operations Office of Compliance Center for Devices and Radiological Health Questions Why did FDA draft the Medical
More informationDETAILED INSPECTION CHECKLIST
FA SC STMT TEXT DETAILED INSPECTION CHECKLIST 500 HEALTH SERVICE SUPPORT Functional Area Manager: HSS Point of Contact: HMC MATTHEW LEONARD/ CAPT ROBERT ALONZO (DSN) 224-4477 (COML) (703) 614-4477 Date
More informationAdministration of Medications A Self-Assessment Guide for Licensed Practical Nurses
Administration of Medications A Self-Assessment Guide for Licensed Practical Nurses March 2018 College of Licensed Practical Nurses of Nova Scotia http://clpnns.ca Starlite Gallery, 302-7071 Bayers Road,
More informationCertified Hazard Control Manager (CHCM) Certified Hazard Control Manager Security (CHCM-SEC) Examination Blueprint/Outline
Certified Hazard Control Manager (CHCM) Certified Hazard Control Manager Security (CHCM-SEC) Examination Blueprint/Outline (Effective October 1, 2017) Exam Domains 145 Items 1. Safety Management 43 Items/30%
More informationRevised! Regulatory Compliance for the Personal Care Products Industry: EU/US/States
Celebrating 50 YEARS 1 9 6 7-2 0 1 7 Revised! Regulatory Compliance for the Personal Care Products Industry: EU/US/States October 19 20, 2017 New Brunswick, NJ Directed by: Jennifer R. Martin, Global Director
More informationMDUFA Performance Goals and Procedures Process Improvements Pre-Submissions Submission Acceptance Criteria Interactive Review
Page 1 MDUFA Performance Goals and Procedures... 3 I. Process Improvements... 3 A. Pre-Submissions... 3 B. Submission Acceptance Criteria... 4 C. Interactive Review... 5 D. Guidance Document Development...
More informationTHE PREVENTIVE CONTROLS RULES AND THE FSPCA
THE PREVENTIVE CONTROLS RULES AND THE FSPCA Dr. Robert Brackett, Illinois Institute of Technology International Citrus & Beverage Conference Clearwater Beach, FL September 17, 2015 Food Safety Modernization
More informationVALUE ANALYSIS TEAM POLICY
VALUE ANALYSIS TEAM POLICY PURPOSE The purpose of this policy is to define the structure and operation of the Value Analysis Team (VAT) process, through active participation, facilitation, and support
More informationFDA s ectd Mandate for 2017: Latest Developments. Phillip DeNoble, PharmD, B.Sc.
FDA s ectd Mandate for 2017: Latest Developments Phillip DeNoble, PharmD, B.Sc. 5 2 Nothing to disclose Disclosure 3 Presentation Overview Introduction/Background Good Review Practices Refuse to Receive
More information(b) Service consultation. The facility must employ or obtain the services of a licensed pharmacist who-
420-5-10-.16 Pharmacy Services. (1) The facility must provide routine and emergency drugs and biologicals to its residents, or obtain them under an agreement described in 483.75(h) of Title 42 Code of
More informationUpdate on FDA-EMA QbD Pilot
Update on FDA-EMA QbD Pilot Presented by: Sharmista Chatterjee, PhD Branch Chief (Acting) Office of Process & Facility Office of Pharmaceutical Quality CDER, FDA Dolores Hernán, PhD Quality Office Specialized
More information